Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 5:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,120 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Newborn Infants Clear all
Completed No phase listed Observational Accepts healthy volunteers

Point of Care Ultrasound Measurements of Perioperative Edema in Infants With Congenital Heart Disease

NCT04151160
View directory record Official record
Conditions
Congenital Heart Disease, Edema, Fluid Overload
Interventions
Point of care ultrasound measurements
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
0 Days to 12 Months
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Jun 26, 2026, 5:34 PM EDT
Completed Phase 2 Interventional

Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs

NCT00198289
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Aurexis® (tefibazumab)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
7 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Jun 26, 2026, 5:34 PM EDT
Completed No phase listed Observational

Bone Health of People With Cystic Fibrosis

NCT00008762
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
8 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 26, 2026, 5:34 PM EDT
Recruiting Not applicable Interventional

Supraglottic Airway for Resuscitation Trial

NCT07150923
View directory record Official record
Conditions
Neonatal Resuscitation, Delivery Room Resuscitation, Positive Pressure Ventilation, Infant, Newborn, Supraglottic Airway, Laryngeal Mask Airways, Implementation Research
Interventions
Enhanced Standard of Care ("Enhanced"), Enhanced Standard of Care ("Enhanced-Plus")
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Days and older
Enrollment
36,503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
30
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Chula Vista, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 26, 2026, 5:34 PM EDT
Completed Phase 2 Interventional

A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101

NCT04947124
View directory record Official record
Conditions
Sturge-Weber Syndrome (SWS), Glaucoma, Glaucoma Congenital, Ocular Hypertension
Interventions
QLS-101ophthalmic solution 1%, QLS-101ophthalmic solution 2%
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Jun 26, 2026, 5:34 PM EDT
Completed No phase listed Observational

Study of Non-Invasive Regional Oxygen Saturations in Pediatric Patients Undergoing Cardiac Catheterization

NCT00939224
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Model 7600 Regional Oximeter System
Device
Lead sponsor
Nonin Medical, Inc
Industry
Eligibility
Up to 12 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Stanford, California • Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2011 · Synced Jun 26, 2026, 5:34 PM EDT
Terminated Phase 3 Interventional Results available

A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP

NCT04634604
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Bevacizumab, Laser
Drug · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
Up to 6 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
32
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Irvine, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jun 26, 2026, 5:34 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion

NCT02070744
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-661, Ivacaftor, Placebo matched to VX-661, Placebo matched to Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Birmingham, Alabama • Palo Alto, California • Stanford, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Jun 26, 2026, 5:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using the Electronic Health Record to Guide Management of Newborn Weight Loss

NCT03655314
View directory record Official record
Conditions
Breastfeeding, Breastfeeding, Exclusive, Morbidity;Perinatal, Feeding, Bottle
Interventions
NEWT, Usual care
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Hours to 96 Hours
Enrollment
2,682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Jun 26, 2026, 5:34 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term

NCT03801252
View directory record Official record
Conditions
Obesity, Induction of Labor Affected Fetus / Newborn
Interventions
Cefazolin, Placebo, Azithromycin
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Jun 26, 2026, 5:34 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A

NCT02629393
View directory record Official record
Conditions
Molybdenum Cofactor Deficiency, Type A
Interventions
ORGN001 (formerly ALXN1101)
Drug
Lead sponsor
Origin Biosciences
Industry
Eligibility
1 Day to 5 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Detroit, Michigan • Cincinnati, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Jun 26, 2026, 5:34 PM EDT
Completed No phase listed Observational

A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome

NCT04007536
View directory record Official record
Conditions
Mucopolysaccharidosis II
Interventions
No Intervention
Other
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
Up to 30 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Oakland, California • Chapel Hill, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2024 · Synced Jun 26, 2026, 5:34 PM EDT
Completed No phase listed Observational

Factors Predictive of Adverse Postoperative Outcomes in Children Undergoing Tonsillectomy

NCT01669993
View directory record Official record
Conditions
Tonsillectomy Postoperative Adverse Events
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 17 Years
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Jun 26, 2026, 5:34 PM EDT
Completed Not applicable Interventional Results available

Nasal Noninvasive NAVA in the Very Low Birth Weight Infant

NCT01785563
View directory record Official record
Conditions
Inadequate; Pulmonary Ventilation, Newborn, Infant, Very Low Birth Weight
Interventions
Nasal NIV-NAVA
Device
Lead sponsor
Tarah T Colaizy
Other
Eligibility
7 Days to 1 Year
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Jun 26, 2026, 5:34 PM EDT
Completed Not applicable Interventional

The Effectiveness of Silver Alginate (Algidex) Patch in the Prevention of Central Line Infections in Very Low Birth Weight Infants

NCT00964093
View directory record Official record
Conditions
Central Line Bloodstream Infections
Interventions
Silver Alginate
Device
Lead sponsor
Baylor Research Institute
Other
Eligibility
1 Day to 3 Weeks
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jun 26, 2026, 5:34 PM EDT
Completed No phase listed Observational

Coping Compliance and Adjustment in Adolescents With Cystic Fibrosis

NCT00577252
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Akron Children's Hospital
Other
Eligibility
13 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 23, 2009 · Synced Jun 26, 2026, 5:34 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Study to Assess the Safety and Efficacy of ANG003

NCT07450547
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions
ANG003 Dose A, ANG003 Dose B, Creon
Drug
Lead sponsor
Anagram Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
26
States / cities
Long Beach, California • Los Angeles, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jun 26, 2026, 5:34 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

NCT06154447
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-828, Placebo, Itraconazole, Midazolam, Tezacaftor, VX-118, Deutivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
12
States / cities
Hollywood, Florida • Orlando, Florida • Overland Park, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 26, 2026, 5:34 PM EDT
Terminated Phase 1 Interventional Results available

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

NCT02527681
View directory record Official record
Conditions
Bacterial Infections
Interventions
Ceftobiprole medocaril
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
Up to 3 Months
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Loma Linda, California • Los Angeles, California • South Bend, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Jun 26, 2026, 5:34 PM EDT
Completed Not applicable Interventional

Leucine-enriched Essential Amino Acid Intake to Optimize Protein Anabolism in Children With Cystic Fibrosis

NCT01172301
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Essential amino acid intake + Leucine vs total AA supplement
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
10 Years to 21 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Jun 26, 2026, 5:34 PM EDT
Completed Not applicable Interventional

Impact of an Orthotic Garment on Gross Motor Skills for Infants With Down Syndrome

NCT04603352
View directory record Official record
Conditions
Down Syndrome
Interventions
Hip Helpers home program
Other
Lead sponsor
University of St. Augustine for Health Sciences
Other
Eligibility
3 Months to 15 Months
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
San Marcos, California • Saint Augustine, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Jun 26, 2026, 5:34 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

NCT01931839
View directory record Official record
Conditions
Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Interventions
Lumacaftor Plus Ivacaftor Combination, Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
1,164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
91
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Jun 26, 2026, 5:34 PM EDT
Completed Not applicable Interventional

NICUSeq: A Trial to Evaluate the Clinical Utility of Human Whole Genome Sequencing (WGS) Compared to Standard of Care in Acute Care Neonates and Infants

NCT03290469
View directory record Official record
Conditions
Rare Diseases
Interventions
clinical whole genome sequencing (cWGS)
Other
Lead sponsor
Illumina, Inc.
Industry
Eligibility
1 Day to 120 Days
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Orange, California • St Louis, Missouri • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Jun 26, 2026, 5:34 PM EDT
Recruiting No phase listed Observational

The Myelin Disorders Biorepository Project

NCT03047369
View directory record Official record
Conditions
Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus Merzbacher Like Disease, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
23
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Jun 26, 2026, 5:34 PM EDT